Where to go with new expensive treatments in NSCLC

British Journal of Cancer

Volumn 78, Issue 2, 1998, Pages 159-162

  Webb, A ^a   O'Brien, M E R ^a  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; DOCETAXEL; GEMCITABINE; IFOSFAMIDE; IRINOTECAN; MITOMYCIN; NAVELBINE; PACLITAXEL; PLATINUM DERIVATIVE; TOPOTECAN; VINBLASTINE; VINDESINE;

ARTICLE; DRUG COST; HUMAN; LEUKOPENIA; LUNG NON SMALL CELL CANCER; PHARMACOECONOMICS; PRIORITY JOURNAL;

EID: 0031813683     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/bjc.1998.458     Document Type: Article

References (32)

1. Belani CP, Einzig A, Bonoim P, Dobbs T, Kozak C, Cohen L and Capozzoli MJ (1997) Multi-institutional phase II trial of docetaxel and carboplatin combination in patients with stage IIIB and IV non-small cell lung cancer. Lung Cancer 18 (suppl. 1): 16
2. Bonomi P, Kim C, Kugler K and Johnson D (1997) Results of a phase III trial comparing taxol-cisplatin regimens to etoposide-cisplalin in non-small cell lung cancer. Lung Cancer 18 (suppl. 1): 10 (abstract 28)
3. Bunn PA Jr (1997) Defining the role of paclitaxel in lung cancer: summary of recent studies and implications for future directions. Semin Oncol 24 (suppl. 12): 153-162
4. Crino L (1997) Combination chemotherapy with Gemeitabine in non-small cell lung cancer. Lung Cancer 18 (suppl. 2): 115
5. Crino L, Clerici M, Figoli F, Carlini P, Ceci G, Cortesi E, Carpi A, Santini A, Di Costanzo F, Boni C, Scarcella L, Santucci A and Ballatori E (1995) Chemotherapy of advanced non-small-cell lung cancer: a comparison of three active regimens. A randomized trial of the Italian Oncology Group for Clinical Research (G.O.I.R.C.). Ann Oncol 6. 347-353
6. 2) in stage IIIA (N2) non-small cell lung cancer. Lung Cancer 18 (suppl. 1): 64
7. Fisher B, Dignam J, Wolmark N, DeCillis A, Emir B, Wickerham DL, Bryant J, Dimitrov NV, Abramson N, Atkins JN, Shibata H, Deschenes L and Margolese RG (1997) Tamoxifen and chemotherapy for lymph node negative, estrogen positive breast cancer. J Natl Cancer Inst 89: 1673-1682
8. Fossella FV (1997) Docetaxel for non-small cell lung cancer. Lung Cancer 18 (suppl. 2): 62-63
9. Fukuoka M (1997) Camptothecins. Lung Cancer 18 (suppl. 2): 57
10. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, Kuriyama T, Ariyoshi Y, Negoro S, Masuda N, Nakajima S and Taguchi T (1992) A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 10: 16-20
11. Gandara DR, Crowley J, Livingston RB, Perez EA, Taylor CW, Weiss G, Neefe JR, Hutchins LF, Roach RW, Grunberg ST, Braun TJ, Natale RB and Balcerzak SP (1993) Evaluation of cisplatin intensity in metastatic non-small cell lung cancer: a phase III study of the Southwest Oncology Group. J Clin Oncol 11: 873-878
12. Giaccone G, Postmus P, Debruyne C, Splinter T, Diaz-Puente M, van Zandwijk N, Ardizzoni A, Scagliotti G, van Meerbeeck J, Festen J, Curran D, Sahmoud T for the EORTC LCCG (1997) Final results of an EORTC phase III study of paclitaxel versus teniposide, in combination with cisplatin, in advanced NSCLC (meeting abstract). Proc Am Soc Clin Oncol 16: 460a
13. Gil Deza E, Balbiani L, Coppola F, Blajman C, Block JF, Giachella O, Chacon R, Capo A, Zori Comba A, Fein L, Polera L, Matwiejuk M, Jaremtchuk A, Muro H, Reale M, Bass C, Chiesa G, Van Koten M and Schmilovich A (1996) Phase III siudy of navelbine (NVB) vs NVB plus cisplatin in non small cell lung cancer (NSCLC) Stage IIIB or IV (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 15 (abstract 1193): 394
14. Gralla RJ, Casper ES, Kelsen DP, Braun DW Jr, Dukeman ME, Martini N, Young CW and Golbey RB (1981) Cisplatin and vindesine combination chemotherapy for advanced carcinoma of the lung: a randomized trial investigating two dosage schedules. Ann Intern Med 95: 414-420
15. Griesinger F, Kern W, Binder L, Hannemann P, Crice CP, Hemmerlein B, Hess CF, Wormann B, Schmidberger H, Herse B and Hiddeman W (1997) Phase II study of taxotere/carboplatin with pharmacokinetics and -dynamics in NSCLC for downstaging in stage IIIB and palliation in stage IV. Eur J Cancer 33 (suppl. 8): S232
16. Hansen HH (1997) The effect of Gemcitabine in non-small cell lung cancer. Lung Cancer 18 (suppl 2): 60-61
17. IMPACT (1995) Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicenter Pooled Analysis of Colon Cancer Trials (IMPACT) investigators (see comments). Lancet 345: 939-944
18. Johnson SAN (1997) Focus on Naveline. Boulogne, France: Pierre Fabre
19. Klastersky J, Seulier JP, Ravez P, Libert P, Michel J, Vandermoten G, Rocmans P, Bonduelle Y, Mairesse M, Michiels T, Thiriaux J, Mommen P, Dalesio O and the EORTC Lung Cancer Working Party (1986) A randomized study comparing a high and a standard dose of cisplatin in combination with etoposide in the treatment of advanced non-small-cell lung carcinoma. J Clin Oncol 4: 1780-1786
20. Le Chevalier T (1997) Vinorelbine (Navelbine) in non-small cell lung carcinoma. Lung Cancer 18 (suppl. 2): 58-59
21. Le Chevalier T, Brisgand D, Pujol JL, Douillard JY, Monnier A, Riviere A, Chomy P, Le Groumellec A, Ruffie P, Gottfried M, Gaspard MH, Chevreau C, Alberola V, Cigolari S, Besson F, Martinez A, Besenval M, Berthaud P and Tursz T (1996) Randomized study of Navelbine registered and cisplatin versus vindesine and cisplatin versus Navelbine registered alone in 612 patients with advanced non-small cell lung cancer (NSCLC). Bull Cancer 83: 385-394
22. Lopez-Cabrerizo MP, Cardenal F, Artal A, Lomas M, Alberola V, Massuti B, Barnetto I, Diaz N, Lianes P, Montalar J, Vadell C, Gonzalez JL, Carrato A, Anton A, Aranda E. Garcia M and Rosell R (1997) Gemcitabine plus cisplatin versus etoposide plus cisplatin in advanced non-small cell lung cancer: a randomised trial by the Spanish lung cancer group, Lung Cancer 18 (suppl. 1): 10 (abstract 27)
23. Masuda N, Fukuoka M, Fujita A, Kurita Y, Tsuchiya S, Nagao K, Negoro S, Nishikawa H, Katagami N, Nakagawa K and Niitani H (1998) A phase II trial of combination of CPT-11 and cisplatin for advanced non-small-cell lung cancer. Br J Cancer 78: 251-256
24. Mattson K, Saarinen A and Jekunen A (1997) Combination treatment with docetaxel (Taxotere) and platinum compounds for non-small cell lung cancer. Semin Oncol 24 (suppl. 14): 5-8
25. Maynard A and Bloor K (1997) Regulating the pharmaceutical industry (editorial). Br Med J 315: 200-201
26. Perng RP, Chen YM, Ming Liu J, Tsai CM, Lin WC, Yang KY and Whang Peng J (1997) Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study. J Clin Oncol 15: 2097-2102
27. Ramanathan RK and Belani CP (1997) Chemotherapy for advanced non-small cell lung cancer: past, present, and future. Semin Oncol 24: 440-454
28. Rosell R, Gomez Codina J, Camps C, Maestre J, Padille J, Canto A, Mate JL, Li S, Roig J, Olazabal A, Canela M, Ariza A, Skacel Z, Morera Prat J and Abad A (1994) A randomized trial comparing preoperative chemotherapy plus surgery with surgery alone in patients with non-small-cell lung cancer. New Engl J Med 330: 153-158
29. Roth JA, Fossella F, Komaki R, Ryan MB, Putnam JB Jr, Jin Soo L, Dhingra H, De Caro L, Chasen M, McGavran M, Atkinson EN and Waun Ki H (1994) A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 86: 673-680
30. Schutte W, Bork I, Wollschlager B and Schadlich S (1997) Phase II trial of docetaxel and carboplatin in the treatment of advanced non-small cell lung cancer. Eur J Cancer 33 (suppl. 8): S238
31. Wozniak AJ, Crowley JJ, Balcerzak SP, Weiss GR, Laufman LR, Baker LH, Fisher RI, Bearman SI, Taylor SA and Livingston RB (1996) Randomized phase III trial of cisplatin (CDDP) vs CDDP plus navelbine (NVB) in treatment of advanced non-small cell lung cancer (NSCLC) report of a Southwest oncology group study (SWOG-9308) (meeting abstract). Proc Annu Meet Am Soc Clin Oncol 15 (abstract 1110): 374
32. Yokoyama A, Kurita Y, Saijo N, Tamura T, Nada K, Shimokata K and Matsuda T (1998) Irinotecan and Cisplatin plus concurrent radiotherapy for unresectable stage III non-small lung cancer. Br J Cancer 78: 257-262